---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-012022"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:24:58.202409+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology reports record Q3 revenue $17.0M, net income $4.5M, first data licensing deal up to $8M

## Summary
- Revenue up 42% YoY to $17.0M; net income of $4.5M vs loss of $2.6M in prior year quarter.
- Adjusted EBITDA $5.2M; gross margin improved to 61% from prior 35% on cost reductions.
- Signed first major data licensing agreement worth up to $8.0M; hired Matt Newman as EVP/GM for data platform.
- Year-to-date revenue $44.6M (+23% YoY); net income $6.5M vs loss of $7.1M in prior nine months.
- No debt; cash $3.2M; expects quarterly revenue fluctuations but positioned for sustained profitability.

## SEC filing metadata
- accession: 0001628280-25-012022
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828025012022/0001628280-25-012022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828025012022/csbr-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-012022
- JSON: https://secwatch.observer/filing/0001628280-25-012022.json
- Plain text: https://secwatch.observer/filing/0001628280-25-012022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.